*Communicable Diseases Intelligence*, Year 2023, Volume 47

https://doi.org/10.33321/cdi.2023.47.28

Publication date: 25/05/2023

http://health.gov.au/cdi

Australian Gonococcal Surveillance Programme, 1 April to 30 June 2022

Monica M Lahra, Siobhan Hurley, Sanghamitra Ray and Tiffany R Hogan

# Introduction

The National Neisseria Network (NNN), Australia, established in 1979, comprises reference laboratories in each state and territory. Since 1981, the NNN has reported data for the Australian Gonococcal Surveillance Programme (AGSP), on antimicrobial susceptibility profiles for Neisseria gonorrhoeae isolated from each jurisdiction for an agreed group of agents. The antibiotics reported represent current or potential agents used for the treatment of gonorrhoea, and include ceftriaxone, azithromycin, ciprofloxacin and penicillin. More recently, gentamicin susceptibilities are included in the AGSP Annual Report.

Ceftriaxone, combined with azithromycin, is the recommended treatment regimen for gonorrhoea in the majority of Australia. However, there are substantial geographic differences in susceptibility patterns across Australia, with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxycillin, probenecid, and azithromycin is recommended for the treatment of gonorrhoea. Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP has a programme-specific quality assurance process.

# Results

Table 1 provides a summary of the proportion of Neisseria gonorrhoeae isolates resistant to azithromycin, ciprofloxacin and penicillin for Quarter 2 2022.

****Table 1: Gonococcal isolates resistant to azithromycin, ciprofloxacin, and penicillin, Australia, 1 April to 30 June 2022, by state or territory****

| Jurisdiction | Number of isolates tested | Resistancea |
| --- | --- | --- |
| Q2, 2022 | Azithromycin | Ciprofloxacin | Penicillin |
| n | % | n | % | n | % |
| Australian Capital Territory | 40 | 0 | 0 | 21 | 52.5 | 17 | 42.5 |
| New South Wales | 767 | 16 | 2.1 | 589 | 76.8 | 300 | 39.1 |
| Queensland | 312 | 1 | 0.3 | 143 | 45.8 | 111 | 35.6 |
| South Australia | 125 | 0 | 0 | 63 | 50.4 | 47 | 37.6 |
| Tasmania | 27 | 0 | 0 | 17 | 63.0 | 9 | 33.3 |
| Victoria | 687 | 60 | 8.7 | 498 | 72.5 | 345 | 50.2 |
| Northern Territory non-remote | 23 | 0 | 0 | 4 | 17.4 | 6 | 26.1 |
| Northern Territory remote | 43 | 0 | 0 | 2 | 4.7 | 2 | 4.7 |
| Western Australia non-remote | 103 | 5 | 4.9 | 40 | 38.8 | 41 | 39.8 |
| Western Australia remote | 25 | 0 | 0 | 1 | 4.0 | 0 | 0 |
| **Australia** | **2,152** | **82** | **3.8** | **1,378** | **64.0** | **878** | **40.8** |

a Resistance as defined by jurisdictional reporting criteria.

## Ceftriaxone

The AGSP has historically reported the category of ceftriaxone decreased susceptibility (DS) at minimum inhibitory concentration (MIC) values ≥ 0.06 mg/L, and has further differentiated those isolates with a MIC ≥ 0.125 mg/L in line with the 2012 World Health Organization criteria.1 In the second quarter of 2022, 4.1% of N. gonorrhoeae isolates had MIC values ≥ 0.06 mg/L, continuing the sharp rise in proportion of these isolates seen in the first quarter of 2022, as shown in Table 2. Of ongoing concern is the increasing proportion of N. gonorrhoeae with ceftriaxone MICs ≥ 0.125 mg/L, with thirteen such isolates reported; the majority of such isolates were reported from New South Wales (7) with other instances reported from Victoria (3), non-remote Western Australia (2) and South Australia (1). Jurisdictional genomic investigations are in progress.2

## Azithromycin

In the second quarter of 2022, the proportion of isolates resistant to azithromycin in Australia was 3.8% (Table 2), higher than in the first quarter of 2022 (2.2%) but remaining lower than the annual proportions reported nationally in 2021 (4.7%) and 2020 (3.9%). It should be noted that there is variation in antimicrobial susceptibility testing methodology in the jurisdictions and so resistance is defined accordingly. The AGSP trend data for azithromycin resistance since 2010 is shown in Table 2.Globally, there have been reports of increased azithromycin resistance in N. gonorrhoeae, heightened since dual therapy was introduced.3 Of note, two isolates from New South Wales and Queensland exhibited high-level resistance to azithromycin, defined as MIC values ≥ 256 mg/L. In the second quarter of 2022, all jurisdictions reported isolates with resistance to azithromycin, except for the Australian Capital Territory, the Northern Territory, South Australia, Tasmania and remote regions of Western Australia.

Dual therapy using ceftriaxone plus azithromycin is the recommended treatment for gonorrhoea as a strategy to temper development of more widespread ceftriaxone resistance. Patients with infections in extragenital sites, where the isolate has decreased susceptibility to ceftriaxone, should have test of cure cultures collected. Continued surveillance to monitor N. gonorrhoeae with elevated MIC values, coupled with sentinel site surveillance in high-risk populations, remain essential to inform therapeutic strategies, identify incursion of resistant strains, and detect instances of treatment failure.

# Author details

Monica M Lahra1, 2

Siobhan Hurley3

Sanghamitra Ray1

Tiffany R Hogan1

1. The World Health Organization Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW, 2031, Australia
2. School of Medical Sciences, Faculty of Medicine, the University of New South Wales, Kensington, NSW 2052 Australia.
3. NSW Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW, 2031, Australia

## Corresponding author

Professor Monica M Lahra

The World Health Organization Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, NSW Health Pathology Microbiology, The Prince of Wales Hospital, Randwick, NSW, 2031, Australia.

Telephone: +61 2 9382 9054

Facsimile: +61 2 9382 9098

Email: monica.lahra@health.nsw.gov.au

# References

1. World Health Organization (WHO). Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO; 2012. Available from: https://apps.who.int/iris/handle/10665/44863.
2. Lahra MM, Shoushtari M, George CRR, Armstrong BH, Hogan TR. Australian Gonococcal Surveillance Programme Annual Report 2020. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.58.
3. Unemo M. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15:364. doi: https://doi.org/10.1186/s12879-015-1029-2.

****Table 2: Percentage of gonococcal isolates with ceftriaxone MIC values 0.06 and ≥ 0.125 mg/L and resistance to azithromycin, Australia, 2010 to 2021 and 1 January to 31 March 2022 and 1 April to 30 June 2022.****

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Year | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 Q1 | 2022 Q2 |
| Number of isolates tested nationally | 4,100 | 4,230 | 4,718 | 4,897 | 4,804 | 5,411 | 6,378 | 7,835 | 9,006 | 9,668 | 7,222 | 6,254 | 1,812 | 2,152 |
| Ceftriaxone MIC 0.06 mg/L | 4.80% | 3.20% | 4.10% | 8.20% | 4.80% | 1.70% | 1.65% | 1.02% | 1.67% | 1.19% | 0.87% | 0.83% | 3.97% | 3.53% |
| Ceftriaxone MIC ≥ 0.125 mg/L | 0.10% | 0.10% | 0.30% | 0.60% | 0.60% | 0.10% | 0.05% | 0.04% | 0.06% | 0.11% | 0.07% | 0.03% | 0.33% | 0.60% |
| Total proportion of isolates with ceftriaxone MIC values ≥ 0.06 mg/L | 4.90% | 3.30% | 4.40% | 8.80% | 5.40% | 1.80% | 1.70% | 1.06% | 1.73% | 1.30% | 0.94% | 0.86% | 4.30% | 4.13% |
| Azithromycin resistance | n/a | 1.1% | 1.3% | 2.1% | 2.5% | 2.6% | 5.0% | 9.3% | 6.2% | 4.6% | 3.9% | 4.7% | 2.2% | 3.8% |

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Christina Bareja

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk, Meru Sheel and Steph Williams

**Website**: <http://www.health.gov.au/cdi>

**Contacts**CDI is produced by the Office of Health Protection, Australian Government Department of Health and Aged Care, GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** cdi.editor@health.gov.au

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: cdi.editor@health.gov.au.

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2023 Commonwealth of Australia as represented by the Department of Health and Aged Care

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health and Aged Care, GPO Box 9848, Canberra ACT 2601, or via e-mail to: copyright@health.gov.au

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.
<http://www.health.gov.au/cdna>